

# ASX Announcement

Medibio Limited – 30 Jan 2017



## Early Redemption of Convertible Note

**Sydney, Australia – 30 January 2017: Medibio Limited (MEB or the Company)** is pleased to announce it has negotiated the early repayment of a US\$2.5 million convertible note (Note). The Note was convertible at A\$0.31 per share or repayable in cash at the noteholder's election on April 2018.

The Note was consideration for the April 2015 acquisition of patents covering the use of 24-hour heart rate data for the diagnosis of depression and other mental health disorders. The patents also cover the use of Medibio's technology to determine treatment effectiveness.

Medibio acquired the patents (US patent 6,245,021 and Canadian patent 2,284,553015) for US\$2.5 million with payment deferred for three years. The patent owner could elect to be paid in cash or Medibio shares at a price of A\$0.31 per share. Interest was payable at 8% pa semi-annually on the US\$2.5 million.

Medibio negotiated the early redemption at face value plus interest due until April 2017. The early redemption of the Note was made possible by the November 2016 \$13.5 million capital raising at \$0.40 a share. The Note's early redemprion simplifies the Company's balance sheet and capital structure, removes a potential overhang at \$0.31 per share and saves the Company approximately \$267,000 interest.

<b>Further Information:</b>		Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a>
<b>Medibio Shareholder Enquiries to:</b> Kris Knauer CEO and Director Medibio Limited <a href="mailto:kris.knauer@medibio.com.au">kris.knauer@medibio.com.au</a> T: +61 (0)411 885979	<b>Medibio Media Enquiries to:</b> Peter Taylor NWR Communications <a href="mailto:peter@nwrcommunications.com.au">peter@nwrcommunications.com.au</a> T: +61 (0)412 036 231	

### About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.